Table 2.

Univariable analysis for hospital admission or death among non-complicated COVID-19 patients treated with early antiviral treatment

	HR (95% CI)	p-value
Demographic data
Age (years)*	1.03 (1.01–1.06)	0.007
Sex (male)	0.93 (0.50–1.73)	0.813
Indication
BMI ≥ 30	0.42 (0.06–3.04)	0.387
Chronic respiratory diseases	2.93 (1.46–5.90)	0.003
Uncontrolled diabetes	1.25 (0.17–9.12)	0.825
Chronic hepatic diseases	-	-
Age ≥ 65 years	1.19 (0.50–2.83)	0.701
Immunosuppression	0.87 (0.45–1.69)	0.681
Chronic renal failure	1.22 (0.48–3.12)	0.677
Cardiovascular diseases	0.44 (0.16–1.24)	0.122
Neurodegenerative diseases	-	-
Drug
Molnupiravir	Reference
Nirmatrelvir	0.70 (0.32–1.53)	0.368
Remdesivir	0.59 (0.23–1.55)	0.283
COVID-19 severity
Mild	Reference
Moderate	10.15 (4.04–25.50)	< 0.001
Time from symptoms onset to treatment (days)*	0.85 (0.67–1.09)	0.207
Vaccination
Vaccinated	0.38 (0.15–0.98)	0.045
Time to last dose to diagnosis (days)*	0.99 (0.99–1.01)	0.801
Events
Time from treatment start to VR (days)*	1.06 (1.03–1.09)	< 0.001

 h: Hazard Ratio

*For each year or day